Onconetix

Biotechnology
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

$2.2M

Market Cap • 1/30/2026

2018

(8 years)

Founded

2022

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country